Ovid Therapeutics (OVID) Other Non Operating Income (2021 - 2026)
Ovid Therapeutics' (OVID) quarterly Other Non Operating Income came in at $858000.0 in Q1 2026, down 62.94% YoY from $2.3 million in Q1 2025, and down 96.09% on a QoQ basis from $22.0 million in Q4 2025.
Ovid Therapeutics (OVID) Other Non Operating Income (2021 - 2026) Analysis & Trends
Ovid Therapeutics (OVID) has 6 years of Other Non Operating Income data on file, last reported at $858000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 62.94% year-over-year to $858000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.6 million (down 26.44% YoY) and the FY2025 annual result came in at $25.0 million, down 29.41% from the prior year.
- Other Non Operating Income declined to $858000.0 in Q1 2026, from $22.0 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $29.0 million in Q2 2024 to a low of -$780000.0 in Q3 2024.
- A 5-year average of $4.1 million and a median of $858000.0 in 2026 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 1546.15% in 2024, down 200.52% in 2024.
- Tracing OVID's Other Non Operating Income over 5 years: stood at $668123.0 in 2022, then soared by 329.11% to $2.9 million in 2023, then tumbled by 48.76% to $1.5 million in 2024, then soared by 1394.69% to $22.0 million in 2025, then tumbled by 96.09% to $858000.0 in 2026.
- The last three Other Non Operating Income figures came in at $858000.0 (Q1 2026), $22.0 million (Q4 2025), and $365000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 858,000.00 |
| Dec 31, 2025 | 21.96 Mn |
| Sep 30, 2025 | 365,000.00 |
| Jun 30, 2025 | 389,000.00 |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Sep 30, 2024 | -780,000.00 |
| Jun 30, 2024 | 29.04 Mn |
| Mar 31, 2024 | 5.72 Mn |
| Dec 31, 2023 | 2.87 Mn |
| Sep 30, 2023 | 776,000.00 |
| Jun 30, 2023 | 1.76 Mn |
| Mar 31, 2023 | 1.54 Mn |
| Dec 31, 2022 | 668,123.00 |
| Sep 30, 2022 | 836,085.00 |
| Jun 30, 2022 | -284,127.00 |
| Mar 31, 2022 | 209,050.00 |
| Mar 31, 2021 | 500,000.00 |